Delcath Systems (NASDAQ:DCTH) Announces Earnings Results, Misses Expectations By $0.01 EPS

Delcath Systems (NASDAQ:DCTH) issued its quarterly earnings data on Thursday. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01), RTT News reports. The company had revenue of $15.10 million for the quarter, compared to the consensus estimate of $14.96 million. Delcath Systems had a negative return on equity of 338.16% and a negative net margin of 150.70%. During the same period in the prior year, the company earned ($0.48) EPS.

Delcath Systems Trading Down 1.7 %

Delcath Systems stock traded down $0.22 during trading hours on Friday, reaching $13.00. 54,623 shares of the stock were exchanged, compared to its average volume of 324,748. The stock has a 50 day moving average of $14.40 and a two-hundred day moving average of $11.63. Delcath Systems has a twelve month low of $3.70 and a twelve month high of $16.97. The company has a market cap of $415.66 million, a P/E ratio of -9.70 and a beta of 0.82.

Wall Street Analysts Forecast Growth

DCTH has been the topic of several research analyst reports. HC Wainwright raised their price objective on Delcath Systems from $22.00 to $24.00 and gave the stock a “buy” rating in a research note on Friday. Craig Hallum raised their target price on shares of Delcath Systems from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Friday, January 17th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Delcath Systems has a consensus rating of “Moderate Buy” and a consensus price target of $22.75.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.